Kathy S. Albain

Papers

Total Citations

H-Index

About

Dr. Kathy S. Albain is a leading oncologist and researcher whose work has profoundly shaped the treatment of breast cancer, particularly through her expertise in tumor biology, prognostic markers, and clinical trial design. She is best known for her pivotal contributions to understanding the role of endocrine therapy and chemotherapy in hormone receptor-positive breast cancer, as well as her leadership in defining the utility of genomic assays like Oncotype DX to guide treatment decisions. Her research has directly influenced international guidelines, helping to spare many women from unnecessary chemotherapy. Among her most notable achievements, Dr. Albain has served as a principal investigator for major SWOG (Southwest Oncology Group) trials, including the landmark S8814 and S1007 studies, which have been cited thousands of times and have changed practice worldwide. Her work on the interaction between tumor biology and patient outcomes has been recognized with numerous awards, including the ASCO Statesman Award. With a career spanning decades and a citation count exceeding 20,000, Dr. Albain remains a transformative figure in precision oncology, dedicated to translating complex biological insights into tangible benefits for patients.